FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical preparations and concerns a method for producing a stable solution of GLP-1 solution whereat a solution of said peptide is heated up at temperature specified within 50 to 95 °C, pH being approximately 8.0 to 10.5 and heating process takes a period within 3 min to 180 min.
EFFECT: invention allows higher stability of the preparation.
12 cl, 18 ex, 20 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| STABILISED PHARMACEUTICAL COMPOSITION CONTAINING PEPTIDE | 2004 |
|
RU2421236C2 |
| GLP-1-BASED COMPOSITIONS AND THEIR APPLICATION METHODS | 2018 |
|
RU2777600C2 |
| STABLE NON-AQUEOUS PHARMACEUTICAL COMPOSITIONS | 2008 |
|
RU2472492C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING INSULIN | 2017 |
|
RU2758367C2 |
| USE OF LONG-ACTING GLP-1 PEPTIDES | 2013 |
|
RU2657573C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING AGONIST GLP-1, INSULIN AND METHIONINE | 2010 |
|
RU2537239C2 |
| PHARMACEUTICAL COMPOSITIONS, CONTAINING GLUCAGON-LIKE PEPTIDE 1 (GLP-1) | 2007 |
|
RU2542500C2 |
| PHARMACEUTICAL COMPOSITIONS, CONTAINING GLUCAGON-LIKE PEPTIDE (GLP-1) | 2007 |
|
RU2409349C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY-RELATED DISEASES CONTAINING INSULINOTROPIC PEPTIDE CONJUGATE | 2008 |
|
RU2446816C2 |
| STABLE COMPOSITIONS BASED ON SEMAGLUTIDE AND THEIR USE | 2019 |
|
RU2803237C2 |
